NanoBioCel: Grupo de Micro y Nano Tecnologías, Biomateriales y Células - GIC 21/005
Universidad de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadoras/es de Universidad de Navarra (11)
2022
2020
-
Cells, Materials, and Fabrication Processes for Cardiac Tissue Engineering
Frontiers in Bioengineering and Biotechnology, Vol. 8
2019
-
Preclinical safety of topically administered nanostructure lipid carriers (NLC) for wound healing application: biodistribution and toxicity studies
International Journal of Pharmaceutics, Vol. 569
2018
-
Autologous bioscaffolds based on different concentrations of platelet rich plasma and synovial fluid as a vehicle for mesenchymal stem cells
Journal of Biomedical Materials Research - Part A, Vol. 106, Núm. 2, pp. 377-385
2016
-
A new strategy to tackle severe knee osteoarthritis: Combination of intra-articular and intraosseous injections of Platelet Rich Plasma
Expert Opinion on Biological Therapy, Vol. 16, Núm. 5, pp. 627-643
2015
-
Cryopreservation of microencapsulated murine mesenchymal stem cells genetically engineered to secrete erythropoietin
International Journal of Pharmaceutics, Vol. 485, Núm. 1-2, pp. 15-24
-
Infiltration of plasma rich in growth factors enhances in vivo angiogenesis and improves reperfusion and tissue remodeling after severe hind limb ischemia
Journal of Controlled Release, Vol. 202, pp. 31-39
2013
-
Advances in the field of tissue engineering and regenerative medicine: State of the art and regulatory issues
Journal of Biomaterials and Tissue Engineering, Vol. 3, Núm. 3, pp. 245-260
2012
-
Optimization of 100 μm alginate-poly-l-lysine-alginate capsules for intravitreous administration
Journal of Controlled Release, Vol. 158, Núm. 3, pp. 443-450
2011
-
Pharmacokinetic/pharmacodynamic evaluation of amoxicillin, amoxicillin/clavulanate and ceftriaxone in the treatment of paediatric acute otitis media in Spain
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 29, Núm. 3, pp. 167-173
2008
-
Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy
Clinical Pharmacokinetics, Vol. 47, Núm. 3, pp. 173-180